There has been tremendous excitement regarding biomarkers that provide in vivo
information on neurodegenerative diseases. Until now, diagnosis has been through clinical …

The improvement of existing techniques and the development of new molecular imaging
methods are an exciting and rapidly developing field in clinical care and research of …

Alzheimer's disease (AD) is the most common cause of dementia in the elderly, with
tremendous impact on the affected individuals and the society. Definitive diagnosis can be …

Amyloid imaging with 18F-labeled radiotracers will allow widespread use, facilitating
research, diagnosis, and therapeutic development for Alzheimer disease. The purpose of …

The incidence of neurodegenerative brain disorders presenting as dementia or
parkinsonism is increasing with population aging. Early and correct diagnosis is essential for …

Radioisotope-based molecular imaging (MI) techniques such as PET/CT and SPECT/CT
aim to integrate patient-specific and disease-specific molecular information with traditional …

Arecent meeting convened by the US Food and Drug Administration (FDA) provides
optimism for the introduction of new molecular imaging agents for clinical use, particularly for …

Although it afflicts an estimated 26.6 million people worldwide—a figure that is expected to
quadruple by 2050—Alzheimer's disease (AD) has yet to be fully understood etiologically …

Biomarkers of Alzheimer disease (AD) can be imaged in vivo and can be used for diagnostic
and prognostic purposes in people with cognitive decline and dementia. Indicators of …

Over the past 35 years or so, PET brain imaging has allowed powerful and unique insights
into brain function under normal conditions and in disease states. Initially, as PET …